Cargando…
Multi-Criteria Decision Analysis for Benefit-Risk Analysis by National Regulatory Authorities
The approval process for pharmaceuticals has always included a consideration of the trade-offs between benefits and risks. Until recently, these trade-offs have been made in panel discussions without using a decision model to explicitly consider what these trade-offs might be. Recently, the EMA and...
Autores principales: | Chisholm, Orin, Sharry, Patrick, Phillips, Lawrence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790083/ https://www.ncbi.nlm.nih.gov/pubmed/35096913 http://dx.doi.org/10.3389/fmed.2021.820335 |
Ejemplares similares
-
Future directions in regulatory affairs
por: Chisholm, Orin, et al.
Publicado: (2023) -
Quantitative Benefit–Risk Assessment of COVID-19 Vaccines Using the Multi-Criteria Decision Analysis
por: Son, Kyung-Hwa, et al.
Publicado: (2022) -
A comparison of various aggregation functions in multi-criteria
decision analysis for drug benefit–risk assessment
por: Menzies, Tom, et al.
Publicado: (2022) -
Stakeholder involvement in Multi-Criteria Decision Analysis
por: Thokala, Praveen, et al.
Publicado: (2018) -
The New Zealand drug harms ranking study: A multi-criteria decision analysis
por: Crossin, Rose, et al.
Publicado: (2023)